{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:28:56Z","timestamp":1759883336062,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["PIP-2015-0056","PUE-2018-574"],"award-info":[{"award-number":["PIP-2015-0056","PUE-2018-574"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["PICT-2016-0440","PICT-2017-0480","PICT-2019-1623"],"award-info":[{"award-number":["PICT-2016-0440","PICT-2017-0480","PICT-2019-1623"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.gene.2021.146110","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T11:25:48Z","timestamp":1639135548000},"page":"146110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Expression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukaemia patients during the first year of imatinib therapy"],"prefix":"10.1016","volume":"813","author":[{"given":"Mar\u00eda Jazm\u00edn","family":"Toloza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yesica","family":"Bestach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8769-6538","authenticated-orcid":false,"given":"Marco","family":"Lincango-Yupanki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Bordone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romina","family":"Mariano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Tarqui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariel","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Negri","family":"Aranguren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Enrico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6602-4265","authenticated-orcid":false,"given":"Irene B.","family":"Larripa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina B.","family":"Belli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.gene.2021.146110_b0005","doi-asserted-by":"crossref","first-page":"e230","DOI":"10.1038\/bcj.2014.50","article-title":"The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity","volume":"4","author":"Ahmad","year":"2014","journal-title":"Blood Cancer J."},{"issue":"5","key":"10.1016\/j.gene.2021.146110_b0010","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4049\/jimmunol.174.5.2591","article-title":"CD8+ T cell immunity against a tumor\/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells","volume":"174","author":"Antony","year":"2005","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.gene.2021.146110_b0015","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.gene.2021.146110_b0020","doi-asserted-by":"crossref","first-page":"106221","DOI":"10.1016\/j.leukres.2019.106221","article-title":"The dynamic of TNF and IL6 gene expression in chronic myeloid leukemia patients reveals early responders to imatinib","volume":"86","author":"Bestach","year":"2019","journal-title":"Leuk Res."},{"issue":"35","key":"10.1016\/j.gene.2021.146110_b0025","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","article-title":"Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or \u2013intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib","volume":"30","author":"Branford","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.gene.2021.146110_b0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjh.15858","article-title":"Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells","volume":"186","author":"Cayssials","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.gene.2021.146110_b0035","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/leu.2011.239","article-title":"NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice","volume":"26","author":"Chen","year":"2012","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.gene.2021.146110_b0040","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2007-12-128397","article-title":"Development and dynamics of robust T-cell responses to CML under imatinib treatment","volume":"111","author":"Chen","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.gene.2021.146110_b0045","doi-asserted-by":"crossref","first-page":"e55818","DOI":"10.1371\/journal.pone.0055818","article-title":"Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia","volume":"8","author":"Christiansson","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.gene.2021.146110_b0050","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1535-7163.MCT-14-0849","article-title":"The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses","volume":"14","author":"Christiansson","year":"2015","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.gene.2021.146110_b0055","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.exphem.2008.10.001","article-title":"Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL)","volume":"37","author":"Cycon","year":"2009","journal-title":"Exp. Hematol."},{"issue":"7","key":"10.1016\/j.gene.2021.146110_b0060","doi-asserted-by":"crossref","first-page":"e101848","DOI":"10.1371\/journal.pone.0101848","article-title":"Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients","volume":"9","author":"Giallongo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.gene.2021.146110_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2015.00107","article-title":"Myeloid derived suppressor cells in chronic myeloid leukemia","volume":"5","author":"Giallongo","year":"2015","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.gene.2021.146110_b0070","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00432-017-2385-7","article-title":"Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia","volume":"143","author":"Hoffmann","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.gene.2021.146110_b0075","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape","volume":"35","author":"Hsieh","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.gene.2021.146110_b0080","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.gene.2021.146110_b0085","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"IRIS investigators. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.gene.2021.146110_b0090","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.gene.2021.146110_b0095","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.16718","article-title":"Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells","volume":"191","author":"Irani","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.gene.2021.146110_b0100","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24096","article-title":"Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.gene.2021.146110_b0105","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-018-1203-7","article-title":"Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis","volume":"35","author":"Iriyama","year":"2018","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.gene.2021.146110_b0110","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.gene.2021.146110_b0115","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"13","key":"10.1016\/j.gene.2021.146110_b0120","doi-asserted-by":"crossref","first-page":"7749","DOI":"10.1073\/pnas.1332767100","article-title":"T-bet is required for optimal production of IFN-gamma and antigen-specific T cell activation by dendritic cells","volume":"100","author":"Lugo-Villarino","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.gene.2021.146110_b0125","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.gene.2021.146110_b0130","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1189\/jlb.0705358","article-title":"Interleukin-10 and the immune response against cancer: a counterpoint","volume":"78","author":"Mocellin","year":"2005","journal-title":"J. Leukoc Biol."},{"key":"10.1016\/j.gene.2021.146110_b0135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.imlet.2016.09.004","article-title":"Predictive value of serum cytokine levels in chronic myeloid leukemia patients","volume":"179","author":"Petrackova","year":"2016","journal-title":"Immunol. Lett."},{"issue":"10","key":"10.1016\/j.gene.2021.146110_b0140","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nri1708","article-title":"Regulation of MHC class II gene expression by the class II transactivator","volume":"5","author":"Reith","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.gene.2021.146110_b0145","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/blood-2003-07-2365","volume":"103","author":"Rimsza","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.gene.2021.146110_b0150","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/leu.2016.197","article-title":"Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators","volume":"30","author":"Ruiz","year":"2016","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.gene.2021.146110_b0155","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0092-8674(00)80856-9","article-title":"Regulatory T cells: key controllers of immunologic self-tolerance","volume":"101","author":"Sakaguchi","year":"2000","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.gene.2021.146110_b0160","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative CT method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.gene.2021.146110_b0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.leukres.2016.09.019","article-title":"Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli","volume":"50","author":"S\u00f6derlund","year":"2016","journal-title":"Leuk Res."},{"issue":"5","key":"10.1016\/j.gene.2021.146110_b0170","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12185-015-1865-2","article-title":"Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia","volume":"102","author":"Sun","year":"2015","journal-title":"Int. J. Hematol."},{"issue":"2","key":"10.1016\/j.gene.2021.146110_b0175","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2016-09-742049","article-title":"CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression","volume":"129","author":"Tarafdar","year":"2017","journal-title":"Blood"}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111921007058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111921007058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T16:45:38Z","timestamp":1759855538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111921007058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":35,"alternative-id":["S0378111921007058"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2021.146110","relation":{},"ISSN":["0378-1119"],"issn-type":[{"type":"print","value":"0378-1119"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukaemia patients during the first year of imatinib therapy","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2021.146110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"146110"}}